MedTrace Logo

Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas

NCT06914674 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-04-06

No results posted yet for this study

Summary

Tamoxifen for Solid Pseudopapillary Tumor of the Pancreas

Conditions

  • Pancreatic Neoplasms

Interventions

DRUG

Tamoxifen 20 mg

Tamoxifen: 10 mg orally twice daily. Combination therapy: Chemotherapy, radiotherapy, surgery, or other treatments per NCCN guidelines and patient condition.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Guopei Luo Prof, MD · Shanghai Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-20
Primary Completion
2027-02-28
Completion
2028-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06914674 on ClinicalTrials.gov